Eli Lilly's completed $2.8B (up to $3.8B) acquisition of AtaiBeckley — what happens to BPL-003 and VLS-01, and what it does and doesn't mean for patients and investors.
Eli Lilly and Company agreed on July 16, 2026, to acquire AtaiBeckley Inc., the clinical-stage biotechnology company behind an intranasal 5-MeO-DMT program, for approximately $2.8 billion upfront, as reported by CNBC and Fierce Biotech. The deal closed between September 10 and 11, 2026, turning AtaiBeckley into a wholly-owned Lilly subsidiary and removing its shares from Nasdaq.
Under the merger agreement, Lilly paid $6.75 in cash for each outstanding AtaiBeckley share. Shareholders also received one Contingent Value Right (CVR) per share, providing conditional payments of up to $2.50 per share if specific development and regulatory milestones are met for the BPL-003 and VLS-01 programs. If every milestone is satisfied, total consideration reaches approximately $3.8 billion. Deal-term and closing figures here are corroborated identically by BioPharma Dive and Investing.com's report on the underlying SEC filing.
AtaiBeckley was created in November 2025, when atai Life Sciences and Beckley Psytech completed a strategic combination that valued Beckley Psytech at roughly $390 million, concentrating several intranasal and short-duration psychedelic programs into a single company. Before this acquisition, AtaiBeckley traded publicly on Nasdaq under the ticker ATAI.
On closing, AtaiBeckley notified Nasdaq of the completed merger and requested that trading in its shares be suspended. Nasdaq was asked to file a Form 25 with the SEC to remove the shares from listing and registration, and AtaiBeckley said it intends to file a Form 15 to terminate its SEC reporting obligations entirely. All AtaiBeckley board members and executive officers resigned at closing, replaced by designees of Lilly's merger subsidiary. AtaiBeckley's standalone investor relations site went offline afterward, consistent with its new status as a private subsidiary.
The acquisition's central asset is BPL-003, an investigational intranasal formulation of 5-MeO-DMT (mebufotenin) in development for treatment-resistant depression (TRD). BPL-003 previously met its primary endpoint in a Phase 2b trial that enrolled 193 patients across 38 sites in six countries: a single 8 mg dose cut MADRS scores by 12.1 points at Day 29, with no drug-related serious adverse events.
The FDA has granted BPL-003 Breakthrough Therapy Designation for TRD. That status lets the sponsor get intensive guidance from senior FDA staff during development and allows rolling review of a completed marketing application. It does not mean the drug is safe, effective, or approved for prescription.
The deal also brought Lilly VLS-01, an investigational N,N-DMT program under evaluation for major depression, and EMP-01, an R-MDMA research program. Changing owners does not change any of these compounds' legal status. 5-MeO-DMT and N,N-DMT remain Schedule I under the federal Controlled Substances Act, and every program still has to complete a full Phase 3 trial and FDA review before any drug could reach a pharmacy.
AtaiBeckley's main competitor in the 5-MeO-DMT race, GH Research (GH001), is not part of this deal and remains an independent company. See our full AtaiBeckley vs GH Research comparison for the clinical head-to-head.
This is the first full acquisition of a clinical-stage psychedelic drug developer by a major global pharmaceutical company. Psychedelic drug development has so far been funded mostly by venture capital and small public biotechs. A company the size of Lilly committing up to $3.8 billion signals that a mainstream pharma player sees real commercial potential in short-duration neuroplastogens. Independent biotechs routinely face balance-sheet constraints when funding late-stage trials: a confirmatory Phase 3 depression program needs hundreds of clinical sites, rigorous placebo-controlled protocols, and years of safety follow-up. Lilly brings established clinical-development systems, global regulatory teams, and deep cash reserves that a standalone biotech usually cannot match.
The sector's downside risk is just as real. In August 2024, the FDA issued a Complete Response Letter rejecting Lykos Therapeutics' MDMA-assisted therapy application for PTSD, requiring another Phase 3 trial. That is proof a late-stage psychedelic program can still fail after years of positive data. Investors and analysts often point to Johnson & Johnson's Spravato (esketamine), an FDA-approved nasal-spray antidepressant for treatment-resistant depression, as the commercial comparison point for a future intranasal 5-MeO-DMT product. Spravato is not a classic psychedelic and is not part of this transaction.
Nothing changes this week for a patient with treatment-resistant depression. BPL-003 and VLS-01 are still unapproved, investigational compounds, and no clinic can prescribe or administer either one outside a formal trial. Commercial availability requires completing Phase 3 studies, securing FDA approval, and in most real-world cases a DEA rescheduling action, none of which this acquisition changes. 5-MeO-DMT and N,N-DMT remain Schedule I, so use outside an authorized study is illegal.
The only lawful way to access BPL-003 or VLS-01 today is by enrolling in an authorized clinical trial operating under an active Investigational New Drug application and monitored by an institutional review board. Use our clinical trial finder to see what is actively enrolling.
Former AtaiBeckley shareholders can no longer trade ATAI. Nasdaq suspended the ticker when the deal closed, and the stock is being delisted and deregistered with the SEC. Shareholders as of closing are entitled to $6.75 per share in cash, disbursed through their brokerage or transfer agent.
Former shareholders also hold one CVR per share, worth up to $2.50 more in cash if BPL-003 and VLS-01 hit their specified development and regulatory milestones. That payout is genuinely uncertain: if Lilly halts development or a milestone is missed, the CVR expires without value, and psychiatric clinical programs fail at meaningful rates. This section is general information. It is not investment advice. For the rest of the publicly traded psychedelic-medicine sector, see our psychedelic stocks and ETFs guide.
Lilly gets two still-investigational neuroplastogen programs and a much bigger balance sheet behind them, but no approved medicine and no faster path to one this week. For patients, nothing about clinical access changes today. For investors, the independent ATAI pure-play no longer exists; what remains is a CVR tied entirely to future trial and regulatory outcomes. That assessment would change quickly if Phase 3 data fails to replicate the Phase 2b results, the way Lykos's MDMA program stumbled in 2024, or if it holds up and pushes BPL-003 toward a Spravato-style approval.
Yes. Eli Lilly and Company acquired AtaiBeckley Inc. in a merger agreement announced July 16, 2026, that closed between September 10 and 11, 2026, making AtaiBeckley a wholly-owned Lilly subsidiary. All AtaiBeckley board members and executive officers resigned at closing.
Lilly paid $6.75 per share in cash upfront, plus one Contingent Value Right (CVR) of up to $2.50 per share tied to BPL-003/VLS-01 development and regulatory milestones. That is an aggregate equity value of roughly $2.8 billion upfront, up to about $3.8 billion total if every CVR milestone is met.
No. Following the close, AtaiBeckley asked Nasdaq to suspend trading in ATAI shares and to file a Form 25 removing them from listing and registration, and AtaiBeckley intends to file a Form 15 to end its SEC reporting obligations. Former shareholders received cash plus a CVR. They no longer hold ongoing AtaiBeckley equity.
No. BPL-003 (intranasal 5-MeO-DMT) holds FDA Breakthrough Therapy Designation for treatment-resistant depression, which speeds up review but is not approval. It still has to complete Phase 3 trials and full FDA review. 5-MeO-DMT remains a Schedule I controlled substance.
Lilly now owns and funds AtaiBeckley's pipeline: BPL-003 (5-MeO-DMT), VLS-01 (N,N-DMT), and EMP-01 (R-MDMA). Ownership changing does not change their legal status. Every compound is still investigational and still Schedule I, and each still needs Phase 3 data and FDA approval before it can be prescribed.
No. The acquisition is a corporate ownership change. It is not a treatment-availability event. BPL-003 and VLS-01 remain unapproved and Schedule I; the only lawful way to access either today is by enrolling in an authorized clinical trial.
Get psychedelic research & policy updates
New trials, FDA decisions, and legal changes for psychedelic — delivered when they happen.
Suggest a tool, topic, or improvement that would make this site more useful.